
    
      This is a single-arm, single-center, open-label Phase II clinical study. The purpose of this
      study was to evaluate the effect of SHR6390 combined with anastrozole on the proliferative
      activity of HR-positive HER2-negative breast cancer tumor cells before surgery.
    
  